Metagenomi Therapeutics Revenue 2022-2026 | MGX
Metagenomi Therapeutics revenue from 2022 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
|
Metagenomi Therapeutics Annual Revenue (Millions of US $) |
|
|---|---|
| 2025 | $25 |
| 2024 | $52 |
| 2023 | $45 |
| 2022 | $17 |
| 2021 | $0 |
|
Metagenomi Therapeutics Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2026-03-31 | $1 |
| 2025-12-31 | $4 |
| 2025-09-30 | $9 |
| 2025-06-30 | $9 |
| 2025-03-31 | $4 |
| 2024-12-31 | $10 |
| 2024-09-30 | $12 |
| 2024-06-30 | $20 |
| 2024-03-31 | $11 |
| 2023-12-31 | $12 |
| 2023-09-30 | $12 |
| 2023-06-30 | $11 |
| 2023-03-31 | $9 |
| 2022-12-31 | |
| 2021-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.052B | $0.025B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |